prod:prod_dcx-login
Cepheid
Équipe de rédaction
Suivre
Partager
Lecture de 5 m
10 janvier 2025
SANTÉ RESPIRATOIRE
Article
Point-of-care PCR testing yields cost savings for influenza-like illnesses
A health economic analysis published in the Journal of Medical Economics reveals significant improvements in clinical and economic outcomes with point-of-care (POC) PCR testing vs POC antigen or send-out PCR strategies for respiratory illnesses.
The POC PCR strategy utilized Xpert Xpress CoV-2/Flu/RSV plus, a multiplex PCR test for the detection of four respiratory viruses simultaneously: SARS-CoV-2, Flu A, Flu B, and respiratory syncytial virus (RSV.) Improved outcomes were attributed to fast and accurate test results.
Despite a higher per-test cost for POC PCR, efficiencies were gained by lower numbers of total tests administered and the highest proportion of correct treatments, yielding lower treatment costs compared to the other testing strategies. POC PCR testing with Xpert Xpress saved $196 – $269 per patient compared to send-out PCR and antigen strategies, respectively. POC PCR testing with Xpert Xpress also resulted in lower resource utilization and clinical consequences, including hospitalizations and ICU admissions.
As healthcare decision-makers work to optimize resources in increasingly challenging financial environments, health economic studies such as this cost-consequence model will be important evaluation tools.
Study co-author, Jordan Chase explains, “It can be hard to look at different diagnostic approaches that have varying up-front costs and performance characteristics and understand whether higher initial expenditure for higher quality can lower costs downstream. Health economic modeling helps us make these assessments.” Chase concludes, “In this case, we found that the reductions in downstream costs from repeat testing, hospitalizations, and other healthcare resources more than compensated for the incremental up-front costs of using Xpert compared to antigen testing.”
With the endemic stage of COVID-19 intersecting other serious respiratory infections, the Xpert Xpress CoV-2/Flu/RSV plus testing strategy is poised to provide significant gains in economic and clinical outcomes for patients, providers, and health systems.
Référence :
- Davies S et al. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses. J. Med Econ. 2024, DOI:10.1080/13696998.2024.2313391
Was this article helpful?
Lire la suite
PLUS D’INFORMATIONS
